Kidswell Bio Corporation Logo

Kidswell Bio Corporation

Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.

4584 | T

Overview

Corporate Details

ISIN(s):
JP3386460004
LEI:
Country:
Japan
Address:
中央区新川一丁目2番12号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kidswell Bio Corporation is a biopharmaceutical company focused on the research and development of innovative pharmaceuticals and therapeutics, with a particular emphasis on pediatric diseases. Formerly known as Gene Techno Science and founded in 2001, the company's operations are centered around three core business segments: Biosimilars, leveraging its expertise in cell line development and CMC; New Biologics, which includes the development of novel antibodies for cancer and eye diseases; and Cell Therapy, which pioneers next-generation cellular medicines based on SHED (Stem cells from Human Exfoliated Deciduous teeth) to address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:44
Registration Form
確認書
Japanese 8.1 KB
2025-11-14 07:43
Interim Report
半期報告書-第26期(2025/04/01-2026/03/31)
Japanese 189.9 KB
2025-06-30 08:33
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2025-06-27 08:36
Registration Form
確認書
Japanese 8.0 KB
2025-06-27 08:35
Governance Information
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.2 KB
2025-06-27 08:33
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-03-31 09:16
Regulatory News Service
臨時報告書
Japanese 18.2 KB
2024-12-26 07:56
Registration Form
有価証券届出書(組込方式)
Japanese 543.7 KB
2024-11-14 07:50
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-14 07:47
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 185.0 KB
2024-06-27 09:12
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-27 09:11
Governance Information
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:11
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 09:10
Annual Report
有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-07 08:39
Regulatory News Service
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all Kidswell Bio Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kidswell Bio Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kidswell Bio Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden
ORX
ORGANIGRAM GLOBAL INC. Logo
Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.
United States of America
OGI
Organon & Co. Logo
A global healthcare company focused on women's health, biosimilars, and established brands worldwide.
United States of America
OGN
Oric Pharmaceuticals, Inc. Logo
Developing therapies to overcome resistance in lung and prostate cancer.
United States of America
ORIC
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland
ORNAV
Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.